This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/drug/DB08828/identifier/kegg-drug/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08828/identifier/drugbank/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08828/identifier/national-drug-code-directory/
n6http://www.rxlist.com/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://www.drugs.com/mtm/
n21http://linked.opendata.cz/resource/drugbank/drug/DB08828/identifier/chebi/
n20http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08828/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08828/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08828
rdf:type
n3:Drug
n3:description
Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
n3:dosage
n22:271B578A-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009 Sep 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19726763 # Sandhiya S, Melvin G, Kumar SS, Dkhar SA: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7. doi: 10.4103/0976-500X.107628. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23662017
n3:group
approved
n3:halfLife
The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.
n3:indication
Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
owl:sameAs
n15:DB08828
dcterms:title
Vismodegib
adms:identifier
n8:50242-140-01 n9:PA166048558 n10:DB08828 n11:D09992 n12:Vismodegib n21:66903
n3:mechanismOfAction
Mutations of the Hedgehog pathway may results in uncontrolled proliferation of skin basal cells. Vismodegib binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway.
n3:patent
n20:7888364
n3:routeOfElimination
Vismodegib is mostly excreted unchanged, and the main route of elimination is by the feces (82%) and the urine accounts for 4.4%.
n3:synonym
Hedgehog Antagonist GDC-0449 Erivedge Vismodegibum GDC-0449
n3:toxicity
Increased risk of embryo-fetal death and significant birth defects. Common adverse event include muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.
n3:volumeOfDistribution
Vismodegib has a volume of distribution of 16.4 to 26.6 L.
n16:hasAHFSCode
n18:10-00%20
n3:foodInteraction
Food does not affect absorption.
n3:proteinBinding
Vismodegib is highly protein bound with plasma protein binding at about 99%. Vismodegib binds to the plasma proteins, albumin and alpha-1-acid glycoprotein (saturable bnding).
foaf:page
n6:erivedge-drug.htm n19:vismodegib.html
n3:IUPAC-Name
n4:271B578F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5795-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5794-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5791-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5792-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5793-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B57A5-363D-11E5-9242-09173F13E4C5 n4:271B578D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B57A6-363D-11E5-9242-09173F13E4C5 n4:271B578E-363D-11E5-9242-09173F13E4C5 n4:271B578B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B578C-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B57A7-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:L01XX43
n3:H-Bond-Acceptor-Count
n4:271B579B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B579C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5796-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5797-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5799-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5798-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B579A-363D-11E5-9242-09173F13E4C5
n3:absorption
The absolute bioavailability of a single dose is 31.8%. Absorption is saturable and is not affected by food.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
879085-55-9
n3:Bioavailability
n4:271B57A1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B57A3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B57A4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B57A0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B579F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B57A2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5790-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B579D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B579E-363D-11E5-9242-09173F13E4C5